Anti-N-methyl-D-aspartate receptor encephalitis: The clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  Liba, Zuzana ^a   Kayserova, Jana ^a   Elisak, Martin ^a   Marusic, Petr ^a   Nohejlova, Hana ^a   Hanzalova, Jitka ^a   Komarek, Vladimir ^a   Sediva, Anna ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Anti N methyl D aspartate receptor encephalitis; CXCL10 chemokine; CXCL13 chemokine; Cytokines; T cell

Indexed keywords

B CELL ACTIVATING FACTOR; CHEMOKINE; CXCL13 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; CXCL10 PROTEIN, HUMAN; CXCL13 PROTEIN, HUMAN; STEROID;

ADOLESCENT; ADULT; ANTI N METHYL D ASPARTATE RECEPTOR ENCEPHALITIS; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CHILD; CLINICAL ARTICLE; COMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PLEOCYTOSIS; PROTEIN DETERMINATION; RANKIN SCALE; T LYMPHOCYTE; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; CASE REPORT; CEREBROSPINAL FLUID; DISEASE COURSE; IMMUNOTHERAPY; METABOLISM; PLASMA EXCHANGE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CHEMOKINE CXCL10; CHEMOKINE CXCL13; CHEMOKINES; CHILD; COMA; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; PLASMA EXCHANGE; STEROIDS; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959267591     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0507-9     Document Type: Article

References (26)

1. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157-65.
2. Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescence. Curr Opin Pediatr. 2010;22(6):739-44.
3. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.
4. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effect of antibodies. Lancet Neurol. 2008;7(12):1091-8.
5. Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118:737-43.
6. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinicalobservations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655-67.
7. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 2013;121:2402-14.
8. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversariers and collabolators. Ann N Y Acad Sci. 2010;1183:211-21.
9. Carrette F, Surh CD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol. 2012;24(3):209-17.
10. Liba Z, Sebronova V, Komarek V, Sediva A, Sedlacek P. Prevalence and treatment of anti-NMDA receptor encephalitis. Lancet Neurol. 2013;12(5):424-5.
11. Leypoldt F, Höftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, et al. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol. 2015;72:180-6.
12. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-MNDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.
13. Hachiya Y, Uruha A, Kasai-Yoshida E, Shimoda K, Sato-Shirai I, Kumada S, et al. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-live plasmablast. J Neuroimmunol. 2013;265(1-2):128-30.
14. Graaf MT, Jongste AHC, Kraan J, Boonstra JG, Sillevis Smitt PA, Gratama JW. Flow cytometric characterization of cerebrospinal fluid cell. Cytometry B Clin Cytom. 2011;80(5):271-81.
15. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisäkk P, Ransohoff RM, et al. Chemokines inmultiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129:200-11.
16. Kowarik MC, Cepok S, Sellner J, Grummel V, Weber MS, Korn T, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012;9:93.
17. Esen N, Rainey-Barger EK, Huber AK, Blakely PK, Irani DN. Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13. Glia. 2014;62(9):1452-62.
18. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. 2011;317(5):620-31.
19. Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Verhulst SJ, Ransohoff RM. Expression of CXCR3 and its ligands CXCL9,-10 and -11 in paediatric opsoclonus-myoclonus syndrome. Clin Exp Immunol. 2013;172:427-36.
20. Muehlinghaus G, Cigliano L, Huehn S, Peddinghaus A, Leyendeckers H, Hauser AE, et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood. 2005;105:3965-71.
21. Phares TW, Stohlman SA, Hinton DR, Bergmann CC. Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis. J Virol. 2013;87:3382-92.
22. Peery HE, Day GS, Dunn S, Fritzler MJ, Pruss H, De Souza C, et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmune Rev. 2012;11(12):863-72.
23. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol. 2012;8(11):613-23.
24. Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Colliver JA, Ness JM. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy. J Neuroinflammation. 2013;10:10.
25. Patakas A, Benson RA, Withers DR, Conigliaro P, McInnes IB, Brewer JM, et al. Th17 effector cells support B cell responses outside of germinal centres. PLoS One. 2012;7, e49715.
26. Uzawa A, Mori M, Kuwabara S. Cytokines and chemokines in neuromyelitis optica: pathogenic and therapeutic implications. Brain Pathol. 2014;24(1):67-73.